260
Participants
Start Date
May 23, 2024
Primary Completion Date
May 23, 2028
Study Completion Date
December 31, 2028
Dose Escalation
Drug: GQ1010
Dose Expansion1
Drug: GQ1010 dose 1
Dose Expansion2
Drug: GQ1010 dose 2
Dose Expansion3
Drug: GQ1010 dose 3
phase II
Drug: GQ1010 RP2D
RECRUITING
Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital & Institute, Beijing
RECRUITING
Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin
RECRUITING
Tianjin medical university cancer institute & hospital, Tianjin
RECRUITING
Hubei Cancer Hospital, Wuhan
RECRUITING
The First Affiliated Hospital of Zhengzhou University, Zhengzhou
GeneQuantum Healthcare (Suzhou) Co., Ltd.
INDUSTRY